Top Ten most popular articles on this week

pharmafile | May 15, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus, top 10 

The news this week continues to be dominated by COVID-19 vaccines and treatments, with the NIAID announcing the launch of a second remdesivir trial while French based Sanofi announced it will ship COVID-19 vaccine to the US first. The FDA has also granted Fast Track designation for Moderna’s coronavirus vaccine candidate.

In other news, 100% of multiple myeloma patients responded to Janssen’s investigational CAR T therapy while Eli Lilly’s Retevmo was approved by FDA to treat lung and thyroid cancers.

1. Latest large hydroxychloroquine study suggests it does not help treat COVID-19

The results of another study into the use of hydroxychloroquine in COVID-19 patients has cast further doubts on its effectiveness in treating the virus.

2. French based Sanofi will ship COVID-19 vaccine to the US first

French based pharmaceutical company Sanofi has announced it will ship its COVID-19 vaccine that is in development to the US first.

3. FDA grants Fast Track designation for Moderna’s coronavirus vaccine candidate

The FDA has granted Fast Track designation for Moderna Inc’s mRNA vaccine candidate against the coronavirus.

4. NIAID announces the launch of second remdesivir trial for COVID-19 patients

The US National Institute of Allergy and Infectious Diseases (NAID) has announced that it is enrolling COVID-19 patients in hospital to be tested with Gilead Sciences’ remdesivir combined with Eli Lilly and Incyte’s JAK inhibitor Olumiant.

5. 100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, known as JNJ-4528, in the treatment of relapsed or refractory multiple myeloma.

6. NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in patients who have residual invasive disease in the breast or lymph nodes after receiving neoadjuvant treatment including a HER2-targeted agent.

7. FDA provides new guidelines to accelerate the development of COVID-19 treatments

The FDA has provided new guidelines to researchers studying potential COVID-19 treatments to help speed up the process of their development.

8. Researchers in Denmark testing if senicapoc drug can reduce lung damage in COVID-19 patients

Scientists are studying if senicapoc, a treatment for sickle cell anemia, can be repurposed to mitigate damage to a COVID-19 patient’s lungs.

9. Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a maintenance treatment of moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD).

10. Eli Lilly’s Retevmo approved by FDA to treat lung and thyroid cancers

The FDA has announced that Retevmo (selpercatinib) has been approved to treat both non-small-cell lung cancer (NSCLC) and medullary thyroid cancer.

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content